Organization | Wuzhou Red Cross Hospital

Wuzhou Red Cross Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Wuzhou China (1910)

Organization Overview

First Clinical Trial

2015

NCT02434614

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Wuzhou Red Cross Hospital

Active Ingredients

Drugs in Phase 3 Trials (7)

camrelizumab (2 trials)

cisplatin (platinol) (8 trials)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (2 trials)

gemcitabine (gemzar) (5 trials)

tislelizumab (1 trial)

toripalimab (LOQTORZ) (1 trial)

Drugs in Phase 2 Trials (4)

capecitabine (xeloda) (1 trial)

lapatinib (tykerb) (3 trials)

paclitaxel (taxol) (2 trials)

sintilimab (1 trial)

Drugs in Other Trials (1)

nimotuzumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial APIs: 12